Novartis AG announced on Thursday that its net sales in the second quarter of the fiscal year 2025 grew by 12% to reach $14.05 billion. The pharmaceutical company's net income surged by 24% compared to the corresponding quarter of the year prior to stand at $4.02 billion, while operating income jumped 21% to $4.86 billion. Earnings per share (EPS) advanced 29% to $2.07 compared to the same period of last year, and core EPS soared 23% to $2.42.
"Novartis delivered another strong quarter, with double-digit sales and core operating income growth. We continue to drive strong performance on our ongoing launches for Kisqali, Pluvicto, and Scemblix, demonstrating the replacement power in our portfolio," CEO Vas Narasimhan commented.